{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:35Z","timestamp":1792800935110,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors have demonstrated minimal activity in unselected testicular germ cell tumors (GCTs), largely due to low tumor mutational burden (TMB) and immunologically \u201ccold\u201d tumor microenvironments. Microsatellite instability\u2013high (MSI-H) or mismatch repair deficiency (dMMR), key predictors of response to PD-1 blockade, are exceedingly rare in GCTs. In patients with Lynch syndrome, germline mismatch repair mutations do not uniformly translate to tumor-level MSI-H\/dMMR, creating therapeutic uncertainty. Case Presentation: We report a 33-year-old male with germline MSH2-associated Lynch syndrome who presented with metastatic pure embryonal testicular carcinoma and markedly elevated tumor markers. Imaging demonstrated extensive hepatic and nodal metastases. Following orchiectomy, he was treated with bleomycin, etoposide, and cisplatin (BEP). Given his high-risk disease and germline mutation, pembrolizumab was added starting cycle 2 after shared decision-making, prior to tumor molecular results. Treatment was complicated by neutropenic fever and cytopenias requiring dose reductions and supportive care but no unexpected immune-related adverse events. Tumor markers rapidly declined, and interval imaging demonstrated near-complete resolution of hepatic metastases and significant nodal response. Subsequent next-generation sequencing revealed microsatellite stable (MSS) disease with low TMB (2 mutations\/Mb), without actionable alterations. The patient completed therapy and transitioned to maintenance pembrolizumab. Conclusion: This case highlights the clinical and biologic discordance between germline Lynch syndrome and tumor-level biomarkers in a non-Lynch spectrum malignancy. While combination chemotherapy and immunotherapy was feasible, the observed response is consistent with expected cisplatin sensitivity, and the contribution of pembrolizumab remains unclear. These findings underscore the importance of tumor-specific molecular testing and caution against extrapolating germline status to guide immunotherapy decisions in germ cell tumors.<\/jats:p>","DOI":"10.3389\/fonc.2026.1847167","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:01Z","timestamp":1789533121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["When Lynch syndrome is not MSI-H: embryonal testicular carcinoma treated with combined BEP chemotherapy and immunotherapy despite MSS\/low TMB: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Nicole A.","family":"Lisek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin G.","family":"Kusiel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"Fda approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/onco.13682","article-title":"Pembrolizumab in patients with advanced metastatic germ cell tumors","volume":"26","author":"Tsimberidou","year":"2021","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020428","article-title":"The immune landscape and immunotherapeutic strategies in platinum-refractory testicular germ cell tumors","volume":"16","author":"Evmorfopoulos","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118610","article-title":"Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapy: potential treatment options against testicular germ cell tumors","volume":"14","author":"Schepisi","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8623","article-title":"Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors","volume":"27","author":"Honecker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B7","article-title":"Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment","volume":"62","author":"Mayer","year":"2002","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23291","article-title":"Mismatch repair expression in testicular cancer predicts recurrence and survival","volume":"122","author":"Velasco","year":"2008","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.3.10.1135","article-title":"Mismatch repair gene expression and genetic instability in testicular germ cell tumor","volume":"3","author":"Velasco","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.3.11.1218","article-title":"Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence","volume":"3","author":"Velasco","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188963","article-title":"Molecular features and actionable gene targets of testicular germ cell tumors in a real-world setting","volume":"26","author":"Morales-Grimany","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115233","article-title":"Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact","volume":"217","author":"Venetis","year":"2025","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7680","article-title":"Tumor mutational burden and mismatch repair deficiency discordance as a mechanism of immunotherapy resistance","volume":"19","author":"Bielska","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad063","article-title":"Microsatellite instability in noncolorectal and nonendometrial Malignancies in patients with Lynch syndrome","volume":"115","author":"Elze","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1714533","article-title":"Lynch syndrome-associated colorectal cancer","volume":"379","author":"Sinicrope","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113253","article-title":"Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients","volume":"192","author":"Yu","year":"2023","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S323898","article-title":"Rapid response to pembrolizumab in a chemo-refractory testicular germ cell cancer with microsatellite instability-high","volume":"14","author":"Kawai","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14670","article-title":"Mismatch repair proficient colorectal adenocarcinoma in two patients with Lynch syndrome","volume":"107","author":"Khandakar","year":"2025","journal-title":"Clin Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00675","article-title":"Prevalence and clinical implications of mismatch repair-proficient colorectal cancer in patients with Lynch syndrome","volume":"7","author":"Ranganathan","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:12Z","timestamp":1789533132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1847167"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1847167","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1847167"}}